What is Immunologix?
Immunologix is a specialized provider of bioanalytical and biomarker sciences, offering critical laboratory services that underpin drug development programs. The company excels in areas such as immunogenicity testing, cell-based assays, and comprehensive biomarker analysis. By forming customized scientific partnerships, Immunologix leverages a global team of experts to deliver strategic and technical solutions. Its primary clientele includes biopharmaceutical firms and research organizations aiming to accelerate their drug discovery and development pipelines through high-quality scientific insights.
How much funding has Immunologix raised?
Immunologix has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Immunologix?
With the recent influx of $350K in a large-scale, late-stage funding round, Immunologix is strategically positioned for significant growth. This substantial investment, part of its overall $350K in capital, will likely be directed towards scaling laboratory operations, expanding its scientific team, and potentially investing in new technological platforms. The company's focus on customized partnerships and expert-driven solutions suggests a continued emphasis on enhancing its service portfolio to meet the evolving demands of the biopharmaceutical industry, thereby solidifying its role as a key enabler of drug development.
See full Immunologix company page
